vs
Side-by-side financial comparison of Vita Coco Company, Inc. (COCO) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Vita Coco Company, Inc. is the larger business by last-quarter revenue ($179.8M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 37.3%). Over the past eight quarters, Vita Coco Company, Inc.'s revenue compounded faster (11.7% CAGR vs 10.6%).
The Vita Coco Company, doing business simply as Vita Coco, is an American beverage company which mainly sells coconut water. The largest brand globally in coconut/plant waters, Vita Coco has operations in 31 countries as of 2016. It is a benefit corporation. The company is owned by All Market Inc.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
COCO vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $179.8M | $168.4M |
| Net Profit | $30.5M | — |
| Gross Margin | 39.9% | — |
| Operating Margin | 18.7% | 50.6% |
| Net Margin | 17.0% | — |
| Revenue YoY | 37.3% | 143.7% |
| Net Profit YoY | 61.4% | — |
| EPS (diluted) | $0.50 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $179.8M | — | ||
| Q4 25 | $127.8M | $168.4M | ||
| Q3 25 | $182.3M | $87.3M | ||
| Q2 25 | $168.8M | $82.4M | ||
| Q1 25 | $130.9M | $65.0M | ||
| Q4 24 | $127.3M | $69.1M | ||
| Q3 24 | $132.9M | $51.6M | ||
| Q2 24 | $144.1M | $73.8M |
| Q1 26 | $30.5M | — | ||
| Q4 25 | $5.5M | — | ||
| Q3 25 | $24.0M | $-31.3M | ||
| Q2 25 | $22.9M | $-12.7M | ||
| Q1 25 | $18.9M | $-40.5M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $19.3M | $-29.5M | ||
| Q2 24 | $19.1M | $-61.9M |
| Q1 26 | 39.9% | — | ||
| Q4 25 | 34.9% | — | ||
| Q3 25 | 37.7% | — | ||
| Q2 25 | 36.3% | — | ||
| Q1 25 | 36.7% | — | ||
| Q4 24 | 32.5% | — | ||
| Q3 24 | 38.8% | — | ||
| Q2 24 | 40.8% | — |
| Q1 26 | 18.7% | — | ||
| Q4 25 | 8.0% | 50.6% | ||
| Q3 25 | 15.3% | -11.4% | ||
| Q2 25 | 14.9% | 8.6% | ||
| Q1 25 | 14.7% | -34.0% | ||
| Q4 24 | 3.4% | -6.4% | ||
| Q3 24 | 15.5% | -31.0% | ||
| Q2 24 | 20.8% | 3.5% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 13.2% | -35.9% | ||
| Q2 25 | 13.6% | -15.4% | ||
| Q1 25 | 14.4% | -62.2% | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 14.5% | -57.2% | ||
| Q2 24 | 13.2% | -83.9% |
| Q1 26 | $0.50 | — | ||
| Q4 25 | $0.10 | $0.32 | ||
| Q3 25 | $0.40 | $-0.16 | ||
| Q2 25 | $0.38 | $-0.06 | ||
| Q1 25 | $0.31 | $-0.21 | ||
| Q4 24 | $0.06 | $-0.14 | ||
| Q3 24 | $0.32 | $-0.15 | ||
| Q2 24 | $0.32 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $352.2M | $-302.0M |
| Total Assets | $488.3M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $201.9M | — | ||
| Q4 25 | $196.9M | $167.9M | ||
| Q3 25 | $203.7M | $92.4M | ||
| Q2 25 | $167.0M | $86.1M | ||
| Q1 25 | $153.6M | $114.6M | ||
| Q4 24 | $164.7M | $144.8M | ||
| Q3 24 | $156.7M | $144.7M | ||
| Q2 24 | $150.1M | $189.3M |
| Q1 26 | $352.2M | — | ||
| Q4 25 | $331.5M | $-302.0M | ||
| Q3 25 | $323.7M | $-451.4M | ||
| Q2 25 | $296.9M | $-433.5M | ||
| Q1 25 | $277.9M | $-426.2M | ||
| Q4 24 | $258.8M | $-388.7M | ||
| Q3 24 | $252.1M | $-370.2M | ||
| Q2 24 | $232.0M | $-344.2M |
| Q1 26 | $488.3M | — | ||
| Q4 25 | $461.2M | $465.9M | ||
| Q3 25 | $461.3M | $364.0M | ||
| Q2 25 | $421.1M | $347.1M | ||
| Q1 25 | $384.0M | $324.0M | ||
| Q4 24 | $362.4M | $343.8M | ||
| Q3 24 | $353.1M | $314.1M | ||
| Q2 24 | $323.0M | $352.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-3.9M | $45.2M | ||
| Q3 25 | $39.1M | $-4.3M | ||
| Q2 25 | $21.8M | $-31.4M | ||
| Q1 25 | $-9.8M | $-22.6M | ||
| Q4 24 | $6.9M | $-35.0M | ||
| Q3 24 | $9.3M | $-35.3M | ||
| Q2 24 | $26.9M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-7.1M | — | ||
| Q3 25 | $35.6M | — | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $-10.4M | — | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $8.9M | $-35.5M | ||
| Q2 24 | $26.6M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | — | ||
| Q3 25 | 19.6% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | -7.9% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 6.7% | -68.7% | ||
| Q2 24 | 18.5% | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 0.0% | ||
| Q3 25 | 1.9% | 0.0% | ||
| Q2 25 | 0.6% | 0.0% | ||
| Q1 25 | 0.4% | 0.0% | ||
| Q4 24 | 0.1% | 0.0% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.2% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | -0.70× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | -0.52× | — | ||
| Q4 24 | 2.05× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
